Cellectis to Report Q2 2025 Financial Results on August 4, 2025
ByAinvest
Monday, Jul 28, 2025 4:33 pm ET1min read
CLLS--
Cellectis, a clinical-stage biotechnology company, utilizes its pioneering gene-editing platform TALEN® to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology and pioneers the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [1][2]. Cellectis also has a platform for developing gene therapies in other therapeutic indications, thanks to its in-house manufacturing capabilities, which allow it to control the cell and gene therapy value chain from start to finish [1][2].
Investors and financial professionals can access the conference call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2 [1][2]. The webcast link is available at https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950 [1][2].
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [1][2]. For further information on Cellectis, please visit www.cellectis.com or contact media@cellectis.com [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/28/3122870/0/fr/Cellectis-publiera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-2025-le-4-ao%C3%BBt-2025.html
[2] https://www.stocktitan.net/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-fsw0vxzd4znb.html
Cellectis, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 4, 2025. The company will hold a conference call on August 5, 2025 at 14:00 CET / 8:00 AM ET to discuss the results and update on its activities. The call will be available via phone and webcast.
Paris-based biotechnology company Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) has announced that it will publish its financial results for the second quarter ending June 30, 2025, on August 4, 2025, after the close of the U.S. market [1]. The company will also hold an investor conference call and webcast on August 5, 2025, at 14:00 CET / 8:00 AM ET to discuss the Q2 results and provide an update on its business activities [1].Cellectis, a clinical-stage biotechnology company, utilizes its pioneering gene-editing platform TALEN® to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology and pioneers the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [1][2]. Cellectis also has a platform for developing gene therapies in other therapeutic indications, thanks to its in-house manufacturing capabilities, which allow it to control the cell and gene therapy value chain from start to finish [1][2].
Investors and financial professionals can access the conference call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2 [1][2]. The webcast link is available at https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950 [1][2].
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [1][2]. For further information on Cellectis, please visit www.cellectis.com or contact media@cellectis.com [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/28/3122870/0/fr/Cellectis-publiera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-2025-le-4-ao%C3%BBt-2025.html
[2] https://www.stocktitan.net/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-fsw0vxzd4znb.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet